In conclusion, our studies revealed that adiponectin facilitates the therapeutic efficiency of thrombopoietic agents by stimulating the membrane trafficking of c‐Mpl in MKs, which provides a point for ITP therapy. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.